---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Mechanism of action"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Mechanism of action. Topics: Pan-PPAR agonist: company description of isoform activation, Company rationale for activating all three isoforms, Chemical class: indole sulfonamide small molecule, Transactivation potency and maximal effect at human PPAR isoforms, and 5 further topics. 9 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Pan-PPAR agonist: company description of isoform activation

> “Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor”
> “Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “Lanifibranor is a PPAR agonist designed to activate all three PPAR isoforms in a moderate and equipotent manner, with balanced activation of PPARα and PPARδ, and partial activation of PPARγ.”

Source: [Inventiva EASL Congress 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Abstracts-EASL-2026-EN-05-13-2026.pdf)

<a id="topic-2.1.2.6.1-2"></a>

### Company rationale for activating all three isoforms

> “PPARs are well-characterized nuclear receptor proteins that regulate gene expression, and their relevance for the fibrotic, inflammatory, vascular and metabolic processes that characterize MASH is well-established.”
> “We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with single and dual PPAR agonists.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.6.1-3"></a>

### Chemical class: indole sulfonamide small molecule

> “Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms.”
> “Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile.”

Source: [Boubia et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29446942/)

> “Small molecule”
> “Differentiated structure – not a glitazone”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.6.1-4"></a>

### Transactivation potency and maximal effect at human PPAR isoforms

> “In the transactivation assay (see Supporting Information), IVA337 acts as a pan‐PPAR agonist with moderate and balanced activity on the three PPAR isoforms.”
> “IVA337 50% effective concentration (EC50) levels for the human PPARs (hPPARs) were 1.63E‐06 M for PPARα, 8.49E‐07 M for PPARδ, and 2.28E‐07 M for PPARγ.”
> “The maximal effect (Emax) reached 100% for both hPPARα and hPPARδ and 80% for hPPARγ when compared to fenofibrate, GW501516, and rosiglitazone, respectively.”
> “The potency of IVA337 for PPARα and PPARγ is in the same range as that of fenofibrate (EC50, 2 µM; PPARα) and pioglitazone (EC50, 0.3 µM; PPARγ), two clinically used and well‐tolerated PPAR agonists with a good efficacy/safety ratio.”

Source: [Wettstein et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5678909/)

<a id="topic-2.1.2.6.1-5"></a>

### Isoform potency and PPARγ efficacy relative to pioglitazone

> “This study was designed so as to provide functional and structural insights into the potency, efficacy, and selectivity against PPARα/δ/γ of lanifibranor, seladelpar, and elafibranor.”
> “The EC50 values for PPARα/δ/γ were in small ranges (0.4–5 µM in Figure 1B and 3–14 µM in Figure 2A,B), and therefore, lanifibranor in clinical doses seems to be able to activate all PPAR subtypes at once.”
> “Due to the fact that its efficacies for PPARγ activation often match with those of pioglitazone (Figure 2A vs. Figure 2I, Figure 2B vs. Figure 2J, and Figure 3B vs. Figure 3F), PPARγ-related undesirable side effects (such as weight gain, edema, bone loss, and congestive heart failure) [42] should be closely monitored in the case of lanifibranor.”

Source: [Kamata et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10451623/)

<a id="topic-2.1.2.6.1-6"></a>

### Isoform-specific pathways attributed to each PPAR subtype

> “Among other effects, PPARα agonists reduce TG levels by increasing mitochondrial FA β-oxidation; PPARβ/δ ligands increase HDL-C levels, have anti-inflammatory effects and improve glucose utilization of skeletal muscle, while PPARγ activity exerts antifibrotic effects on activated hepatic stellate cells and improves IS in liver, adipose tissue and skeletal muscle.”
> “The clinical metabolic-immune improvements with lanifibranor indeed substantiate the pan-PPAR activating mechanism across all three subtypes, exemplified by the effects on TG, HDL-C and IR reflecting mainly PPARα, β/δ and γ mediated mechanisms, respectively”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-2.1.2.6.1-7"></a>

### Preclinical efficacy compared with single and dual PPAR agonists

> “In preclinical models, the indole sulfonamide lanifibranor (IVA337), a pan-PPAR agonist, improved insulin sensitivity and macrophage activation and reduced liver fibrosis and inflammatory gene expression with higher efficacy than single or dual PPAR agonists.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

> “Lanifibranor improved all histological features of steatohepatitis in CDAA-HFD-fed mice, including liver fibrosis, thereby combining and exceeding specific effects of the single PPAR agonists.”

Source: [Lefere et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32360434/)

<a id="topic-2.1.2.6.1-8"></a>

### Hepatic stellate cell proliferation and activation

> “IVA337 dose dependently and completely inhibited PDGF‐induced hHSC proliferation (Fig. 7A).”
> “In contrast, the selective PPAR agonists demonstrated only partial effects up to the highest concentrations (Fig. 7A).”

Source: [Wettstein et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5678909/)

> “Lanifibranor was able to fully inhibit the proliferation induced by PDGF and was able to prevent the overexpression of α-SMA and the hallmark of myofibroblast, induced by stiffness.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.1-9"></a>

### Hepatic macrophage activation: PPARδ-dependent effect

> “Lanifibranor attenuated the accompanying inflammatory activation in both murine palmitic acid-stimulated bone marrow-derived macrophages, as well as patient-derived circulating monocytes, in a PPARδ-dependent fashion.”
> “PPARδ agonism and lanifibranor directly modulate macrophage activation, but not infiltration, thereby synergizing with beneficial metabolic effects of PPARα/γ agonists.”

Source: [Lefere et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32360434/)

Additional sources: [Guo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702283/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
